When the type 1 diabetes community saw the potential for a game-changing medical device that automated the delivery of insulin based on the real-time need of the patient, Larry Soler led a JDRF team that developed a strategy involving scientific research, venture philanthropy, overcoming regulatory challenges, and ensuring reimbursement that resulted in the first FDA approved artificial pancreas technology. The device is now widely used by type 1 diabetes patients and is seen by many as the greatest breakthrough in diabetes care since the discovery of insulin.